natgillin/translations-raw huggingface dataset:
The short half-life of 13 minutes accounts for approximately 80% of the area under the plasma concentration curve and governs the initial rapid accrual of plasma drotrecogin alfa (activated) concentrations towards the steady-state.
Kratek razpolovni čas 13 minut velja za približno 80 % področja pod krivuljo plazemske koncentracije in vpliva na hitro začetno naraščanje plazemskih koncentracij drotrekogina alfa (aktiviranega) proti ravnovesnemu stanju.
Patients meeting the clinical diagnosis of severe sepsis had a) known or suspected infection, b) clinical evidence of systemic response to infection including fever or hypothermia, leucopenia or leucocytosis, tachycardia and tachypnoea, and c) acute organ dysfunction.
Bolniki, ki so ustrezali klinični diagnozi hude sepse, so imeli a) znano okužbo ali sum nanjo, b) klinične znake sistemskega odziva na okužbo, vključno s povišano ali znižano telesno temperaturo, levkopenijo ali levkocitozo, tahikardijo in tahipnejo, ter c) akutno okvaro delovanja organov.
There was also no difference in 28-day mortality (17.1% versus 17.3% in the Xigris and placebo groups, respectively).
Tudi ni bilo razlike v 28-dnevni umrljivosti (17,1 % pri bolnikih, ki so jemali zdravilo Xigris, v primerjavi s 17,3 % v skupini s placebom).
Dose escalation or bolus doses of Xigris are not necessary to account for the interruption in the infusion.
Višanje odmerka ali bolusni odmerki zdravila Xigris za nadomeščanje prekinitve infuzije niso potrebni.
In the majority of patients, measurements of Activated Protein C beyond 2 hours after termination of the infusion were below the quantifiable limit, suggesting rapid elimination of drotrecogin alfa (activated) from the systemic circulation.
Pri večini bolnikov so bile meritve aktiviranega proteina C po preteku 2 ur po zaključku infuzije pod zaznavnim pragom, kar kaže na hitro izločanje drotrekogina alfa (aktiviranega) iz sistemskega obtoka.
Changes observed in monkeys at, or in small excess of, the maximum human exposure during repeated dose studies, were all related to the pharmacological effect of Xigris and include beside the expected prolongation of APTT, decreases in haemoglobin, erythrocytes and haematocrit, and increases in reticulocyte count and PT.
Vse spremembe, ki so jih opažali pri opicah pri enakih ali nekoliko večjih odmerkih od največjega odmerka pri ljudeh, med študijami ponovljenega odmerjanja, so bile povezane s farmakološkim učinkom zdravila Xigris in so poleg pričakovanega podaljšanja APTT vključevale znižanja koncentracij hemoglobina, eritrocitov in hematokrita ter povišanje koncentracije retikulocitov in podaljšanje PT.
What Xigris looks like and contents of the pack Xigris is presented as a powder for solution for infusion in a vial.
Izgled zdravila Xigris in vsebina pakiranja Zdravilo Xigris se nahaja v obliki praška za raztopino za infundiranje v viali.
If the infusion is interrupted for any reason, Xigris should be restarted at the 24 μg/kg/hr infusion rate and continued to complete the full recommended 96 hours of dosing administration.
Če je infuzija iz kakršnegakoli vzroka prekinjena, je treba zdravilo Xigris ponovno uvesti s hitrostjo infuzije 24 μg/kg/h in nadaljevati do dopolnitve priporočenih 96 ur dajanja odmerka.
Serious bleeding during the infusion period occurred in 1% (1 in 100) of patient with severe sepsis and in 2.4% (roughly 1 in 40) of patients treated with Xigris, with most bleeding in both groups occurring in the stomach and bowel.
Resne krvavtitve med infuzijo so se pojavljale pri 1 % (1 od 100) bolnikov s hudo sepso in 2,4 % (približno 1 od 40) bolnikov, zdravljenih z zdravilom Xigris, pri tem je bila večina krvavitev v obeh skupinah v želodec in črevo.
Xigris is used to treat adults with severe sepsis.
Zdravilo Xigris uporabljamo za zdravljenje odraslih s hudo sepso.
In patients with severe sepsis, the plasma clearance of drotrecogin alfa (activated) was significantly decreased by renal impairment and hepatic dysfunction, but the magnitude of the differences in clearance (< 30 %) does not warrant any dosage adjustment.
Pri bolnikih s hudo sepso je bil plazemski očistek drotrekogina alfa (aktiviranega) zaradi okvarjenega delovanja ledvic in jeter značilno znižan, vendar velikost razlik očistka (< 30 %) ne upravičuje prilagoditve odmerka.
Xigris is indicated for the treatment of adult patients with severe sepsis with multiple organ failure when added to best standard care.
Zdravilo Xigris je indicirano za zdravljenje odraslih bolnikov s hudo sepso z odpovedjo več organov kot dodatek najboljšemu standardnemu zdravljenju.
Patients received drotrecogin alfa (activated) within 48 hours of onset of the first sepsisinduced organ dysfunction.
Bolniki so drotrekogin alfa (aktiviran) prejeli v 48 urah po pojavu prve motnje delovanja organov, povzročene s sepso.
Bleeding into the brain was uncommon, occurring in 0.2% (1 in 500) of patients treated with Xigris.
Krvavitve v možgane so bile redke in so se pojavljale pri 0,2 % (1 od 500) bolnikov, zdravljenih z zdravilom Xigris.
Not applicable.
Podatek ni potreben.
Plasma concentrations of endogenous Activated Protein C in healthy subjects and patients with severe sepsis are usually below detection limits (< 5 ng/ml) and do not significantly influence the pharmacokinetic properties of drotrecogin alfa (activated).
Plazemske koncentracije endogenega aktiviranega proteina C pri zdravih osebah in bolnikih s hudo sepso so običajno pod pragom zaznave (< 5 ng/ml) in na farmakokinetične lastnosti drotrekogina alfa (aktiviranega) ne vplivajo pomembno.
Caution should be employed when Xigris is used with other drugs that affect haemostasis (see sections 4.3 and 4.4) including Protein C, thrombolytics (e.g. streptokinase, tPA, rPA and urokinase), oral anticoagulants (e.g. warfarin), hirudins, antithrombin, aspirin and other anti platelets agents, e.g. nonsteroidal anti-inflammatory drugs, ticlopidine and clopidogrel, glycoprotein IIb/IIIa antagonists (such as abciximab, eptifibatide, tirofiban) and prostacyclins such as iloprost.
Previdnost je potrebna, kadar zdravilo Xigris uporabljamo skupaj z drugimi zdravili, ki vplivajo na hemostazo (glejte poglavji 4.3 in 4.4), vključno s proteinom C, trombolitiki (npr. streptokinazo, tPA, rPA in urokinazo), peroralnimi antikoagulanti (npr. varfarinom), hirudini, antitrombinom, aspirinom in drugimi zaviralci agregacije trombocitov, npr. nesteroidnimi protivnetnimi zdravili, tiklopidinom in klopidogrelom, antagonisti glikoproteina IIb/IIIa (kot so abciksimab, eptifibatid, tirofiban) in prostaciklini, kot je iloprost.
Paediatrics: Data from a placebo-controlled clinical trial which was stopped for futility after 477 patients 0 to 17 years-old had received the study treatment did not establish efficacy of Xigris in paediatric patients and showed a higher rate of central nervous system bleeding in the Xigris versus placebo group.
Pediatrični bolniki: Rezultati s placebom nadzorovanega kliničnega preskušanja, ki so ga zaradi neuspešnosti prekinili potem, ko je študijsko zdravljenje prejelo 477 bolnikov, starih 0 do 17 let, niso pokazali učinkovitosti zdravila Xigris pri pediatričnih bolnikih in so pokazali višjo stopnjo krvavitve v osrednje živčevje v skupini bolnikov, ki so prejemali zdravilo Xigris, v primerjavi s skupino, ki je prejemala placebo.
No dose adjustments are required in adult patients with severe sepsis with regard to age, gender, hepatic function (as measured by transaminase levels), renal function, obesity or co-administration of prophylactic heparin.
Pri odraslih bolnikih s hudo sepso niso potrebne prilagoditve odmerka glede na starost, spol, jetrno delovanje (kot ga merimo z ravnmi transaminaz), ledvično delovanje, debelost ali sočasno dajanje profilaktičnega heparina.
Patients requiring the administration of ≥ 3 units of packed red blood cells per day for 2 consecutive days without an identified site of bleeding
Bolniki, ki so potrebovali dajanje ≥ 3 enot koncentriranih eritrocitov na dan 2 zaporedna dneva brez ugotovljenega mesta krvavitve.
Exclusion criteria encompassed patients at high risk of bleeding (see sections 4.3 and 4.4), patients who were not expected to survive for 28 days due to a pre-existing, non-sepsis related medical condition, HIV positive patients whose most recent CD4 count was ≤ 50/mm3, patients on chronic dialysis, and patients who had undergone bone marrow, lung, liver, pancreas or small bowel transplantation, and patients with acute clinical pancreatitis without a proven source of infection.
Merila za izključitev so obsegala bolnike z velikim tveganjem za krvavitev (glejte poglavji 4.3 in 4.4), bolnike, za katere niso pričakovali, da bodo preživeli 28 dni zaradi predhodnih zdravstvenih stanj, ki niso bila povezana s sepso, HIV pozitivne bolnike, katerih zadnja koncentracija CD4 je bila ≤ 50/mm3, bolnike zdravljene s kronično dializo, bolnike, ki so imeli presajen kostni mozeg, pljuča, jetra, trebušno slinavko ali tanko črevo, in bolnike z akutnim klinično zaznavnim pankreatitisom brez dokazanega vira okužbe.
Care should be taken to administer Xigris at the appropriate rate, calculated based on kg of bodyweight and infused for the correct duration.
Pri zdravilu Xigris moramo paziti, da ga dajemo z ustrezno hitrostjo, ki jo izračunamo na podlagi kilogramov telesne mase, in da je trajanje infuzije pravilno.
The recommended dose of Xigris is 24 μg/kg/hr (based on actual body weight) given as a continuous intravenous infusion for a total duration of 96 hours.
Priporočeni odmerek zdravila Xigris je 24 μg/kg/h (na osnovi dejanske telesne mase), ki ga dajemo kot neprekinjeno intravensko infuzijo v skupnem trajanju 96 ur.
Xigris should be administered via a dedicated intravenous line or a dedicated lumen of a multilumen central venous catheter.
Zdravilo Xigris je treba dajati po posebnem intravenskem katetru ali posebni svetlini večlumenskega centralnega venskega katetra.
The pharmacokinetics of drotrecogin alfa (activated) were characterised by attainment of steady-state plasma concentration within 2 hours following the start of the infusion.
Za farmakokinetiko drotrekogina alfa (aktiviranega) je bilo značilno doseganje plazemske koncentracije ravnovesnega stanja v 2 urah po začetku infuzije.
Drotrecogin alfa (activated) that is present in a blood or plasma sample drawn from a patient who is being infused with the drug will be gradually neutralized by endogenous plasma protease inhibitors present in the sample.
Drotrekogin alfa (aktiviran), ki je prisoten v vzorcu krvi ali plazme, odvzetem bolniku, ki mu infundiramo zdravilo, bo postopoma nevtraliziran z endogenimi zaviralci proteaz plazme, prisotnimi v vzorcu.
Survival status was assessed in a follow-up study of PROWESS survivors.
V kontrolni študiji preživelih iz študije PROWESS so vrednotili stanje preživetja.
Patients treated with Xigris experienced improved 28-day survival compared to those treated with placebo.
28-dnevno preživetje bolnikov, zdravljenih z zdravilom Xigris, je bilo večje v primerjavi z bolniki, ki so prejemali placebo.
In patients developing antibodies adverse events were not more frequent in drotrecogin alfa (activated) than in placebo patients.
Pri bolnikih, ki so razvili protitelesa, neželeni učinki niso bili bolj pogosti pri bolnikih zdravljenih z drotrekoginom alfa (aktiviranim) kot pri bolnikih s placebom.
In the overall population, the in-hospital mortality was significantly lower in patients on Xigris than in patients on placebo (29.4% vs. 34.6%; p=0.023).
V celotni populaciji je bila umrljivost v bolnišnici značilno nižja pri bolnikih, ki so prejemali zdravilo Xigris, kot pri bolnikih, ki so prejemali placebo (29,4 % v primerjavi s 34,6 %; p = 0,023).
In adult patients in severe sepsis clinical studies, the frequency of anti-human Activated Protein C IgA/IgG/IgM antibodies or neutralizing antibodies is low and is similar between drotrecogin alfa (activated) and placebo-treated patients tested.
V kliničnih študijah hude sepse pri odraslih bolnikih, je pogostnost protiteles IgA/IgG/IgM proti humanemu aktiviranemu proteinu C ali nevtralizirajočih protiteles nizka ter podobna kot med testiranimi bolniki, zdravljenimi z drotrekoginom alfa (aktiviranim) in s placebom.
Treatment should be started within 48 hours, and preferably within 24 hours, of onset of the first documented sepsis-induced organ dysfunction (see section 5.1).
Zdravljenje začnemo v roku 48 ur, najbolje v 24 urah, po pojavu prve zabeležene motnje delovanja organov, ki jo povzroči sepsa (glejte poglavje 5.1).
Drotrecogin alfa (activated) and endogenous human Activated Protein C are inactivated in plasma by endogenous protease inhibitors but the mechanism by which they are cleared from plasma is unknown.
Drotrekogin alfa (aktiviran) in endogeni humani aktivirani protein C v plazmi inaktivirajo endogeni zaviralci proteaz, mehanizem, s katerim ju odstranijo iz plazme, pa ni znan.
When administering drotrecogin alfa (activated) at low flow rates (less than approximately 5 ml/hr), the infusion set must be primed for approximately 15 minutes at a flow rate of
Pri dajanju drotrekogina alfa (aktiviranega) pri nizkih hitrostih pretoka (manj kot približno 5 ml/h) je treba infuzijski sistem pripravljati približno 15 minut s hitrostjo pretoka približno
In each of two randomised, placebo-controlled trials, PROWESS and ADDRESS (see section 5.1), 28day and in-hospital mortality were higher in patients treated with drotrecogin alfa (activated) compared to placebo for the sub-population of patients with single organ dysfunction and recent surgery (n=98 in PROWESS and n=636 in ADDRESS).
V vsakem od dveh randomiziranih s placebom kontroliranih preskušanj, PROWESS in ADDRESS (glejte poglavje 5.1), sta bili 28-dnevna umrljivost in umrljivost v času hospitalizacije višji pri bolnikih, zdravljenih z drotrekoginom alfa (aktiviranim), v primerjavi s placebom, pri podskupini bolnikov z okvarjenim delovanjem enega organa in nedavnim operacijskim posegom (n = 98 v preskušanju PROWESS in n = 636 v preskušanju ADDRESS).
In the multiple organ dysfunction subgroup of ADDRESS the 28-day placebo mortality was 21.9%, similar to the single organ dysfunction subgroup of PROWESS (21.2%), confirming the lack of efficacy in patients with severe sepsis who are at low risk of death.
V podskupini z okvarjenim delovanjem večih organov v preskušanju ADRESS je bila 28-dnevna umrljivost pri bolnikih, ki so prejemali placebo, 21,9%, kar je podobno kot v podskupini z okvarjenim delovanjem enega organa v študiji PROWESS (21,2%), kar potrjuje neučinkovitost pri bolnikih s hudo sepso, ki imajo majhno tveganje za smrt.
In the subgroup of patients with an APACHE II score ≥25 at baseline, the mortality was 31% in the Xigris group (128 out of 414) and 44% in the placebo group (176 out of 403).
V podskupini bolnikov s številom točk po APACHE II ≥ 25 ob izhodišču je bila umrljivost 31 % v skupini zdravila Xigris (128 od 414) in 44 % v skupini placeba (176 od 403).
Because drotrecogin alfa (activated) may affect the APTT assays, drotrecogin alfa (activated) present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).
Ker drotrekogin alfa (aktiviran) lahko vpliva na teste APTT, lahko drotrekogin alfa (aktiviran), prisoten v vzorcih plazme, vpliva na enostopenjske teste koagulacije, ki temeljijo na APTT (kot so testi faktorjev VIII, IX in XI).
• Recent administration (within 7 days) of oral anticoagulants
• Uporaba peroralnih antikoagulantov v zadnjih 7 dnevih
No benefit of drotrecogin alfa (activated) was observed in the subgroup of 872 patients at low risk of death with multiple organ dysfunction, so ADDRESS did not confirm the efficacy results of the PROWESS study.
V podskupini 872 bolnikov z nizkim tveganjem za smrt in z okvarjenim delovanjem večih organov niso opažali nobene koristi drotrekogina alfa (aktiviranega), tako da preskušanje ADDRESS ni potrdilo učinkovitosti rezultatov študije PROWESS.
Xigris was studied in one Phase 3 international, multi-centre, randomised, double-blind, placebocontrolled trial (PROWESS) in 1690 patients with severe sepsis.
Zdravilo Xigris so preučevali v mednarodnem multicentričnem randomiziranem dvojno slepem s placebom kontroliranim preskušanju faze 3 (PROWESS) pri 1690 bolnikih s hudo sepso.
However, a small number of patients in severe sepsis controlled clinical trials received a prior course of drotrecogin alfa (activated).
Vendar je majhno število bolnikov v kliničnih preskušanjih hude sepse predhodno prejelo zdravljenje z drotrekogin alfa (aktiviranim).
The mean steady-state plasma concentration of drotrecogin alfa (activated) in healthy subjects receiving 24 μg/kg/hr is 72 ng/ml.
Povprečna plazemska koncentracija drotrekogina alfa (aktiviranega) ravnovesnega stanja pri zdravih osebah, ki prejemajo 24 μg/kg/h, je 72 ng/ml.
For intravenous infusion after reconstitution and dilution.
Za intravensko uporabo po pripravi in redčenju.
Name and address of the manufacturer of the biological active substance
Ime in naslov izdelovalca biološke zdravilne učinkovine(učinkovin)
The pharmacodynamic effect of drotrecogin alfa (activated) on the APTT assay is dependent on the reagent and instrument used to perform the assay and the time that elapses between sample acquisition and assay performance.
Farmakodinamični učinek drotrekogina alfa (aktiviranega) na test APTT je odvisen tudi od reagenta in inštrumenta, uporabljenih za izvedbo testa, ter časa, ki je pretekel od odvzema vzorca do izvedbe testa.
In patients with severe sepsis, infusion of drotrecogin alfa (activated) from 12 μg/kg/hr to 30 μg/kg/hr rapidly produced steady-state plasma concentrations that were proportional to infusion rates.
Pri bolnikih s hudo sepso je infuzija drotrekogina alfa (aktiviranega) od 12 μg/kg/h do 30 μg/kg/h hitro povzročila plazemske koncentracije ravnovesnega stanja, sorazmerne hitrostim infuzije.
Xigris is supplied as a lyophilised, white to off-white powder.
Zdravilo Xigris je na voljo kot liofiliziran, bel do sivo bel prašek.
A planned interim analysis (with 400 patients enrolled) showed a low likelihood of demonstrating a significant difference in the primary endpoint of “Composite Time to Complete Organ Failure Resolution” (CTCOFR score of 9.8 versus 9.7 mean days over 14 days).
Načrtovana vmesna analiza (s 400 sodelujočimi) je pokazala majhno verjetnost za statistično značilno razliko pri cilju študije “čas do izboljšanja po popolni odpovedi organov” (CTCOFR - Composite Time to Complete Organ Failure Resolution) rezultat - 9,8 proti 9,7 povprečnih dni v obdobju 14 dni).
For procedures with an inherent bleeding risk, discontinue Xigris for 2 hours prior to the start of the procedure.
Pri posegih s tveganjem za krvavitev prenehajte dajati zdravilo Xigris 2 uri pred začetkom posega.
Eli Lilly Nederland B.V., Grootslag 1-5, 3991 RA, Houten, The Netherlands
Eli Lilly Nederland B.V., Grootslag 1-5, 3991 RA, Houten, Nizozemska
Plasma drotrecogin alfa (activated) steady-state concentrations are proportional to the infusion rate over a range of infusion rates from 12 μg/kg/hr to 48 μg/kg/hr.
Plazemske koncentracije drotrekogina alfa (aktiviranega) v ravnovesnem stanju so sorazmerne hitrosti infuzije v razponu hitrosti infuzije od 12 μg/kg/h do 48 μg/kg/h.
Use appropriate aseptic technique during the preparation of Xigris for intravenous administration.
Med pripravo zdravila Xigris za intravensko dajanje uporabljajte ustrezen aseptični postopek.
At 28 days, the overall mortality rates were 24.7% for the Xigris-treated group and 30.8% for the placebo-treated group (p=0.005).
Po 28 dneh je bila celokupna umrljivost bolnikov 24,7 % pri bolnikih, zdravljenih z zdravilom Xigris, in 30,8 % pri bolnikih, ki so prejemali placebo (p = 0,005).
1 vial, powder for solution for infusion.
1 viala, prašek za raztopino za infundiranje
Investigators attributed 2 deaths in the Xigris group and 5 deaths in the placebo group to bleeding events.
Raziskovalci so pripisali krvavitvi 2 smrtna primera v skupini bolnikov, ki so prejemali zdravilo Xigris, in 5 smrtnih primerov v skupini s placebom.
Prophylactic heparin did not increase the risk of serious bleeding compared to placebo (3.9% vs 5.2%, respectively), including CNS bleeding (1.0% vs 0.7%, respectively).
Profilaktični heparin ni povečal tveganja za resno krvavitev v primerjavi s placebom (3,9 % oziroma 5,2 %), vključno s krvavitvijo v CŽS (1,0 % oziroma 0,7 %).
Caution should be employed when Xigris is used with other medicines that affect how your blood clots (for example medicines that dissolve blood clots, thin the blood, or medicines that inhibit platelets such as aspirin, non-steroidal anti-inflammatory medicines, or clopidogrel).
Previdnost je potrebna pri uporabi zdravila Xigris z drugimi zdravili, ki vplivajo na strjevanje krvi (na primer zdravila, ki raztapljajo krvne strdke, redčijo kri ali zdravila, ki zavirajo trombocite, kot je aspirin, nesteroidni antirevmatiki ali klopidogrel).
Special care should be taken with Xigris if you are at risk of bleeding, for example: - if you are taking other medicines which affect how your blood clots (for example medicines that dissolve blood clots, thin the blood, or medicines that inhibit platelets such as aspirin) - if within the last three months, you have had a stroke caused by a blood clot - if you have a known problem with bleeding
Bodite posebno pozorni pri uporabi zdravila Xigris, če pri vas obstaja nevarnost za krvavitev, na primer: - če jemljete druga zdravila, ki vplivajo na strjevanje krvi (na primer zdravila, ki raztapljajo krvne strdke, redčijo kri ali zdravila, ki zavirajo trombocite, kot je aspirin) - če ste v zadnjih treh mesecih doživeli kap, ki jo je povzročil krvni strdek - če ste že imeli težave s krvavitvijo
In the open-label ENHANCE study, the incidence of serious bleeding events during the 28-day study period was 6.5%, and the incidence of CNS bleeds during the 28-day study period was 1.5%.
V študiji z znanim zdravilom ENHANCE je bila incidenca resnih krvavitev v 28-dnevnem trajanju študije 6,5 %, incidenca krvavitev v osrednje živčevje v 28-dnevnem trajanju študije pa 1,5 %.
When adding the reconstituted drotrecogin alfa (activated) into the infusion bag, direct the stream to the side of the bag to minimise the agitation of the solution.
Ko dodajate raztopljeni drotrekogin alfa (aktiviran) v infuzijsko vrečko, usmerite curek v steno vrečke, da čimbolj zmanjšate vrtinčenje raztopine.
Drotrecogin alfa (activated) is contraindicated in children below the age of 18 years (see section 5.1).
Uporaba drotrekogina alfa (aktiviranega) je pri otrocih, mlajših od 18 let, kontraindicirana (glejte poglavje 5.1).
The incidence of serious bleeding events with Xigris was higher in patients with recent [within 30 days] surgery than in “medical” patients without surgery (see section 4.8).
Incidenca resnih primerov krvavitve z zdravilom Xigris je bila višja pri bolnikih, ki so bili nedavno (do vključno pred 30 dnevi) operarirani, kot pri bolnikih, ki niso bili operirani (glejte poglavje 4.8).
In these studies serious bleeding events included any intracranial haemorrhage, any life-threatening or fatal bleed, any bleeding event requiring the administration of ≥ 3 units of packed red blood cells per day for 2 consecutive days, or any bleeding event assessed as serious by the investigator.
V teh študijah so resne krvavitve vključevale katerokoli intrakranialno krvavitev, kakršnokoli smrtno nevarno ali usodno krvavitev, kakršnokoli krvavitev, ki je zahtevala dajanje ≥ 3 enot koncentriranih eritrocitov na dan 2 zaporedna dneva, ali kakršnokoli krvavitev, ki jo je kot resno ocenil preiskovalec.
Xigris is contraindicated in children below the age of 18 years (see also sections 4.2 and 4.3).
Uporaba zdravila Xigris je pri otrocih, mlajših od 18 let, kontraindicirana (glejte poglavji 4.2 in 4.3).